RedChip Companies
|
|
Weekly Newsletter
|
|
|
| |
Industry Leaders Welcome New Study of Save Foods’ Treatment Showing Extended Shelf-Life of Mangos While Virtually Eliminating Post-Harvest Pesticides
|
|
Save Foods (NASDAQ: SVFD) (FSE:80W), an agri-food tech company specializing in eco crop protection that helps to reduce food waste and ensure food safety, announced results of an independent study that shows Save Foods’ treatment can extend the shelf life and freshness of mangos while virtually eliminating the use of post-harvest pesticides.
Approximately 26% of mangos are lost between harvest and consumption. Pesticides are commonly applied in the post-harvest stage in order to reduce the loss of produce to decay. Growing concerns about the toxicity of chemical pesticides as well as increasingly stringent regulations regarding their use, especially in Europe, appear to indicate why there is an increase in the adoption of Save Foods’ eco crop protection treatments. With the recent organic recognition of one of Save Foods’ products, consumers can enjoy long-lasting pesticide-free mangos.
Itay Noked, agronomist and independent researcher (M.Sc. Post-Harvest), commented: “Save Foods’ treatments can be easily applied to fresh produce to prolong storage and reduce post-harvest loss. In the study I have independently performed, after 21 days in storage and 15 days on the shelf, twice as many mangos were still edible, while 75% less pesticides were used. These impressive results are significant for producers, packers, distributors, and retailers, as well as for consumers.”
For more information, visit www.savefoods.co
|
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that it has received approval from the Ethics Committee of The Soroka University Medical Center, in Be'er-Sheva, Israel, to conduct the Company’s clinical trial for SCI-210 in patients suffering from Autism Spectrum Disorder (ASD). The trial will investigate the effect of the Company’s drug candidate SCI-210, a proprietary combination of cannabidiol (CBD) and CannAmide™, versus CBD monotherapy, in treating ASD.
|
BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201
BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, announced that a patent covering the use of terlipressin monotherapy to treat ascites patients who have not progressed to hepatorenal syndrome (HRS) has been issued by the U.S. Patent & Trademark Office. This action restores U.S. patent protection for BIV201 (continuous infusion terlipressin), which had previously been lost due to an Inter Partes Review (“IPR”) challenge to a related patent by another company.
|
|
|
Reklaim Closes $1.3 Million Non-Brokered Private Placement and Streamlines Operations to Cash Neutral.
Reklaim Ltd. (OTCQB: MYIDF) (TSXV: MYID), the destination for consumers to access and reclaim their data, announced the closing of the first tranche of a non-brokered private placement offering comprised of 19,214,406 units at a purchase price of $0.0675 per Unit for aggregate gross proceeds of approximately $1,296,972.
|
Bragg’s ORYX Gaming Goes Live with Jumpman Gaming
ORYX Gaming, a Bragg Gaming Group company (NASDAQ: BRAG, TSX: BRAG), announced that its content is now live across Jumpman Gaming’s network of UK brands, marking a significant step forward for its presence in Europe’s largest market. The partnership agreement with Jumpman Gaming allows ORYX to provide its exclusive RGS content, including content developed by its in-house studios as well as its premium partners, which collectively offers player-favorite features and jackpots designed to drive engagement and retention.
|
|
|
Upcoming Events |
|
|
|
|
| NASDAQ: RNAZ - TransCode Therapeutic |
| 4:15pm Eastern |
| TransCode Therapeutics is developing therapeutic and diagnostic candidates designed to deliver on the promise of RNA in oncology. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas and others. |
|
|
|
|
|
| NASDAQ: DPRO - Draganfly |
| 4:15pm Eastern |
| Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more. |
|
|
|
|
|
| NASDAQ: GENE - Genetic Technologies Limited |
| 4:15pm Eastern |
| Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. |
|
|
|
|
|
| NASDAQ: SVFD - Save Foods |
| 4:15pm Eastern |
| Save Foods Inc and its Israeli subsidiary Save Foods Ltd are innovative, dynamic companies dedicated to delivering integrated eco-friendly solutions for improved safety, freshness and quality, every step of the way from field to fork. |
|
|
Archive Events |
|
|
|
|
| Private - Newt Financial |
| Meeting Duration 47 minutes |
| Newt is a cloud-based Software as a Service (SaaS) platform enabling enterprises to offer digital financial products and services. |
|
|
|
|
|
| NYSE American: GNS - Genius Group |
| Meeting Duration 28 minutes |
| Genius Group is the holding company for GeniusU, Genius Institute and Genius School. GeniusU is an edtech platform providing over 2.6 million students across 200 countries with personalized learning paths and micro-degrees on business building skills. |
|
|
|
|
|
| NASDAQ: IINN - Inspira Technologies |
| Meeting Duration 45 minutes |
| Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. |
|
|
|
|
|
| OTC: ODYY - Odyssey Health Inc. |
| Meeting Duration 50 minutes |
| Odyssey Health Inc. (formerly Odyssey Group International, Inc.) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. |
|
|
Lesson of the Week
The importance of price-to-earnings ratios when comparing stocks.
|
|
|
RedChip TV |
MidSouth Week in Review
Last week was the worst week (-4.8%) for the Dow since 2020.
|
|
|
You are receiving this email because your email is subscribed to our mailing list.
Click here to unsubscribe your email address from this list.
Copyright © 2022. All rights reserved.
|
|
© 2022 RedChip , All rights reserved
|
|
| |
|
| |
